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We describe the development of a proactive pre-conception counselling service for women with epilepsy based on complete
re-investigation of the woman’s epilepsy, a policy of withdrawing antiepileptic drugs (AEDs) thought to carry an increased risk
of foetal abnormality (and substitution, where indicated, of AEDs thought to carry a lesser risk) and the exhibition of folic acid
5 mg daily plus fulfilment of the woman’s educational needs and exploration of her and her partner’s wishes. The outcome of
the assessment of 90 such women is compared with the outcome of 59 women presenting to our service already pregnant.
An audit of the outcomes in the two groups suggests that re-investigation of women pre-conceptually is worthwhile (some
women turn out not to have epilepsy or have cerebral lesions best managed before pregnancy) and that foetal morbidity may
be reduced by judicious rationalization of medication: folic acid taken before conception may also be protective for the foetus.
Proactive pre-conception counselling, however, only works if the woman is prepared to wait (sometimes up to a year) for
necessary drug changes to be instituted and is using reliable contraception.
c© 1999 BEA Trading Ltd
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There is growing interest in the medical, psychologic-
al and social needs of women with epilepsy1: al-
though women in the UK obtain little help with them2
and there is recognition of the necessity to improve
epilepsy services for women3. UK Guidelines for the
management of women with epilepsy have just been
published3. Some AEDs may be particularly likely to
cause foetal abnormality in the offspring of women
who take them in pregnancy4, particularly pheno-
barbitone, phentyoin and sodium valproate: evidence
is also accumulating that carbamazepine, thought to
be relatively safe, may also be more often associ-
ated with major foetal damage than initially thought4.
Most anticonvulsants are also associated with minor
foetal anomalies, such as nail hypoplasia and hyper-
telorism5.
There has been recent UK television and
press publicity for a group of parents who have
formed the Foetal Anticonvulsant Syndrome Group.
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‡Epilepsy Specialist Nurse1059–1311/99/060322 + 06 $12.00/0They rightly assert that medical concern about the ef-
fects of anticonvulsants on the foetus, has concentrated
on major anomalies in the neonate and little atten-
tion has been paid to the subsequent development of
the child, particularly whether intra-uterine AED ex-
posure leads to eventual specific learning and devel-
opmental problems. The evidence that such conditions
are caused by AED intra-uterine exposure is conflict-
ing5, particularly because of numerous confounding
variables and further research is urgently needed.
If the older AEDs are associated with a small but
significant risk of causing major foetal damage (and
an unknown risk of causing future impairment) what
of the newer AEDs? Morrell6 has suggested, based on
the results of animal foetal toxicity studies, that some,
specifically lamotrigine, gabapentin and possibly
tiagabine, may be safer since they exhibit no animal
foetal damage, whereas all the older AEDs do (and
cause animal foetal damage of the same type that they
cause in humankind). Not everyone agrees with this
view and the matter will only be settled by long-term
studies based on the establishment of comprehensive
pregnancy outcome measures in women with epilepsy.c© 1999 BEA Trading Ltd
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Table 1: Pre-conception investigation schedule.
• Full re-investigation of the epilepsy (including EEG studies
and MRI)
• Neurological/general medical/psychiatric history and
examination
• Full blood count, biochemical and thyroid profile (plus B12
and folic acid levels)
• Serum AED levels (where appropriate)
• Sexual/menstrual/contraceptive history: endocrine and
gynaecological screen and examination plus ultrasound
examination where applicable
• Lifestyle history (smoking, exercise, diet, alcohol, illicit
drugs)
• Family/genetic history
• Views of patients and partner
Table 2: Pre-conception questions and action points.
1 Is seizure control the best likely to be achieved?
• If not, improve it.
2 Is the epilepsy lesional?
• If it is lesional, will it complicate potential
pregnancy/delivery?
3 Is there any other medical or endocrine problem?
• If there is, will it prevent conception, or complicate
pregnancy/delivery?
• If yes to 2 or 3 should it be treated before conception?
4 Is there a genetic history (e.g. spina bifida)?
• If yes, refer for genetic advice.
5 Can AED therapy be withdrawn (MRC criteria)?
• If yes, slow withdrawal.
6 Is monotherapy possible?
• By withdrawal of one drug?
• By substituting one drug for another?
7 Is complete drug change needed (e.g. patient on
phenytoin/valproate)?
• Consider substituting ‘safer’ drug.
8 Consider increasing dose frequency of older drug if
withdrawal/substitution is impossible to prevent toxic blood
level peaks (especially valproate).
9 Give all women folic acid 5 mg daily indefinitely if B12 level
is normal.Folic acid (0.4 mg daily) is recommended for all
women to be taken before conception based on good
experimental evidence that it is protective against
spina bifida: it is recommended that women known to
be particularly likely to have a child with spina bifida
should take 4 mg daily7.
In the UK there is no 4 mg tablet: so it is usu-
ally recommended that women with epilepsy take the
available 5 mg tablet pre-conceptually and for at least
3 months post-conception3. There is no evidence that
taking folic acid will prevent spina bifida in such
women, but it is considered that this dose is harmless3.
Pre-conception counselling is discussed in the UK
Guidelines3 which recommend provision of detailed
information about likely AED foetal risks, using the
lowest possible dose of ‘the most appropriate’ AED
and possible AED withdrawal before conception if the
woman satisfies the usual clinical criteria (based on
the Medical Research Council study8) for safe with-
drawal. Being a concensus document, however, the
guidelines do not suggest differential AED withdrawal
(removing the old and leaving the newer AEDs) and
do not suggest substituting newer AEDs for old. Such
a policy would be considered too controversial by
many clinicians.
Some years ago we began to develop a spe-
cific womens clinic in our service, providing pre-
conception advice, advice about contraception, the
conduct of pregnancy and the menopause: this was
based on requests from general practitioners. A previ-
ous study of general practitioners’ epilepsy needs in
the West Midlands9 had suggested that next to pro-
viding a fast-track assessment service for new on-
set seizures, the greatest need was for advice about
women’s issues in epilepsy: at the same time we
provided an advisory service to the adjacent mater-
nity hospital for women with epilepsy presenting, al-
ready pregnant, to the obstetric services. As a result of
our early experiences we drew up a protocol of pre-
conception management of women with epilepsy (out-
lined in the materials and methods section) in which
we decided that we would be proactive and would be
prepared to try to lighten the total burden of AEDs
in women wishing to become pregnant, substituting
newer AEDs where necessary and doing our best to
withdraw phenobarbitone (mysoline), phenytoin and
valproate: all women would be prescribed folic acid
5 mg daily. We were able to compare the eventual
foetal outcome of our pre-conception group with that
of the group of women already pregnant when referred
to our service, seen over the same time period.MATERIALS AND METHODS
Women referred by their general practitioners for pre-
conception advice before becoming pregnant were
fully assessed according to the following schedule (Ta-
ble 1). The aim was to try to answer the following
questions (Table 2). Information counselling was also
carried out and the woman’s fears, needs and under-
standing (and the partners) explored (Table 3).Following investigation joint decisions were made
between the two clinicians, the patient and her partner
about how to proceed, particularly whether to with-
draw from or substitute AEDs: withdrawal of AEDs
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Table 4: Substituting lamotrigine for valproate.
A If patient seizure free on valproate monotherapy.
Lamotrigine
5 mg nightly 2 weeks
10 mg nightly 2 weeks
25 mg nightly 1 month
50 mg nightly 1 month
75 mg nightly 1 month
100 mg nightly 1 month
After one month measure the trough blood level ofwas carried out according to our published clinic
schedule10. If substitution was attempted (usually lam-
otrigine for valproate), or withdrawal would take a
long time, the women were counselled about using
contraception whilst the change in drug regimen was
taking place. All women started folic acid 5 mg daily
at the first consultation. Substitution of lamotrigine
for valproate was accomplished according to our usual
schedule (Table 4). Valproate inhibits the metabolism
of lamotrigine so when the latter is added to a pa-
tient taking valproate, much higher blood levels are
obtained than would be clinically expected: to avoid
a dose dependent hypersensitivity reaction, very small
initial doses of lamotrigine have to be used. The dose
of lamotrigine will also need to be increased pari passu
with the withdrawal of valproate to maintain serum
levels: in some patients a further dose increase is
needed at the end of withdrawal. Withdrawal or sub-
stitution was abandoned if seizures returned or seizure
frequency significantly increased.Table 3: Pre-conception counselling check list.
• Genetics (risk of child having epilepsy)
• Effect of medication on foetus
• Effect of epilepsy on foetus
• Effect of pregnancy on epilepsy
• Management of labour and delivery
• Safety issues during pregnancy
• Breast feeding
• Child/mother safety after delivery
• Prevention of overprotection of the mother
• Possible AED dose increase during last trimester
• Fertility
• Contraception
• What to tell the child
• Emotional health post-deliverya
• Fear of seizures during laboura
Some of these counselling issues would be raised again during the
pregnancy, before delivery and in the puerperium.
aThese two issues were always raised by the patient (see text).
lamotrigine.
If it is considered adequate, withdraw valproate by 1/4 of the
original dose every month, adding in 25 mg of lamotrigine in
the morning at each withdrawal, so at the end of the
withdrawal the patient is taking 100 mg of lamotrigine twice
daily. One month after valproate withdrawal is complete
check the trough level of lamotrigine and increase the dose if
necessary to reach near first blood level. If EEG activitya
returns or there is an occurrence of seizures during
withdrawal, stop withdrawal at least temporarily and increase
dose of lamotrigine to limits of toleranceb and try again.
Abandon withdrawal if there is a threat of further seizure
breakthrough.
B If the patient is not seizure-free on valproate monotherapy, as
A—to 100 mg daily.
If seizures have come under control follow A. If not, using
EEG changesa and seizure frequency on an index increase
dose of lamotrigine to limits of toleranceb. If there is now
seizure control or a significant seizure frequency reduction,
proceed to valproate reduction as in A.
aIn primary generalized epilepsy the return of spike wave activity
or photosensitivity. bDevelopment of neurotoxic symptoms—
diplopia, ataxia, nausea.The notes of all patients referred by their GPs for
pre-conception assessment between January 1995 and
January 1997 were perused for results of investiga-
tions, decisions about drug withdrawal or substitution,
whether this was possible and outcome of any sub-
sequent pregnancy. All women had had delivery by
March 1999. Patients already part of our service who
had pre-conception counselling were not included in
the survey: all included patients were new referrals to
the service. At the same time the notes of 59 women,
already pregnant, referred to our service by the adja-
cent maternity hospital were also examined for foetal
outcome.RESULTS
Ninety women were referred for pre-conception as-
sessment between January 1995 and January 1997.
Four, on assessment, were shown to have non-epileptic
attacks, and one died six weeks after initial assess-
ment, from a hitherto unsuspected invasive tumour
(she had been assured at another centre, on the basis of
CT scanning, that she did not have a cerebral lesion).
The results of investigations are shown in Table 5.Seven patients were found to have potentially se-
rious causes for their epilepsy, which might compli-
cate labour and delivery and previously unsuspected
(one died). Seventeen patients had been seizure-free
for over two years but only six of these were prepared
to totally withdraw from medication before concep-
tion (due to their need to drive). Some drug withdrawal
(and/or substitution) was possible in many patients.
Apart from the six who withdrew completely, the ma-
jority of patients were on monotherapy by concep-
tion. All patients taking phenobarbitone and phenytoin
were able to withdraw from these drugs before con-
ception without return or increase in seizures and all
but two taking valproate (these two ended up on much
smaller doses of valproate but attempts at complete
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able increase in seizures). Substitutions with lamot-
rigine (for valproate mainly) took place in 30 patients
and in two patients with gabapentin. Fourteen patients
withdrew from carbamazepine (Table 5).Table 5: Patients referred for pre-conception assessment,
N = 90c.
Seizure-free for over 2 years 17
Not epilepsy 4
Died before conception 1
Serious abnormality on screen 7
Tumoura 2 (1 fatal)
AVMa 1
Cavernous haemangiomaa 1
Aneurysma 1
Hydatid diseasea 1
Systemic lupusb 1
aTreated surgically before pregnancy. bTreated medically before
pregnancy. cFive of this group had already had at least one child.
Table 6: Pre-conception group AEDs taken, N = 85.
Before Before
counselling conception
Carbamazepine 55 41
Valproate 47 2
Phenytoin 12 0
Lamotrigine 14 44
Benzodiazepines 9 4
Gabapentin 3 5
Vigabatrin 2 2
Phenobarbitone 5 0
Total 147 98
On no therapy 0 6
On monotherapy 34 60
On two drugs 40 19
On more than two drugs 11 0
Table 7: Pregnancy outcome.
Counselled Already
group pregnant
Deliveredc 85 59
Abnormality detected during
pregnancy and terminated 0 3
Abnormality at birth 0 8
Obstetric complications 2a 3b
a Early miscarriage (1) with subsequent normal pregnancy:
premature birth (1). bPremature birth (3). cEight patients took over
a year of unprotected intercourse to achieve conception, but no
patient needed fertility treatment.
fo
Table 8: Foetal abnormalities (in already pregnant group).
Defect Drug(s) taken at conception
Small head/developmental
delay Valproate/carbamazepine
Hydrocephalus/spina bifida
(TERMINATED) Valproate/carbamazepine
Congenital heart disease/
hypospadias Valproate/carbamazepine
Congenital heart disease Valproate/lamotrigine
Congenital heart disease Topirimate/carbamazepine/
vigabatrin
Congenital heart disease/
skeletal deformity Carbamazepine
Congential heart disease Valproate
Congenital heart disease Carbamazepine
Spina bifida (TERMINATED) Valproate/carbamazepine/
Vigabatrin
Spina bifida (TERMINATED) Valproate/carbamazepinea
Multiple skeletal defects NIL
aTwo subsequent normal pregnancies on lamotrigine monotherapy.
None of these patients were taking pre-conceptual folic acid.No women who had counselling had an abnormal
etus in the subsequent pregnancy (one patient hadan early miscarriage, but a normal subsequent preg-
nancy). Eleven of the 59 women already pregnant
at referral had an abnormal foetus (major anomalies
only) three of which were terminated. This is a high
abnormality rate (18%) and probably represents selec-
tive factors operating in this group (though no woman
was referred because she was known to have a foetal
abnormality).The proportion of women in this group taking more
than one anticonvulsant was higher than in the pre-
conception group (Table 9), although several women
had abnormal babies on monotherapy. The type of an-
ticonvulsant taken pre-conceptually was also differ-
ent (Table 10) although the main difference was in
the counselled group taking much less valproate and
more lamotrigine: both groups took about the same
amount of carbamazepine, although carbamazepine
was potentially implicated as monotherapy in two
foetal anomalies (known to be associated with carba-
mazepine)4. However, no patients in the counselled
group were taking a combination of carbamazepine
and valproate, which may be particularly teratogenic.
Table 11 illustrates that no patient in either group tak-
ing folic acid pre-conceptually had a foetal abnormal-
ity, whereas 23% of those women not taking folic acid
did. One other point arose out of this study that is
worth recording. Almost all women in the counselled
group with epilepsy reported:
(a) fear of a seizure during labour:
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puerperal mood disorder.
No patient in the counselled group had a seizure
during labour or delivery, and only one patient had a
brief mild puerperal depressive episode that remitted
spontaneously without medication. Some anticonvul-
sant medication may be protective against mood dis-
order.Table 9: Percentage of women using monotherapy or
polytherapy at conception.
Counselled group Already pregnant group
N = 85 N = 59
Nil 7% 2%a
Monotherapy 71% 32%
Two drugs 22% 46%
More than two drugs 0% 20%
aThis patient had an abnormal foetus.
Table 10: AEDs taken at conception (percentage of total).
Counselled group Already pregnant group
N = 98 N = 109
Carbamazepine 42% 39%
Valproate 2% 41%
Phenytoin 0% 6%
Lamotrigine 45% 2%
Benzodiazepine 4% 8%
Gabapentin 5% 0%
Vigabatrin 2% 2%
Phenobarbitone 0% 2%
Table 11: Folic acid use before conception.
Yes No
97 47
Foetal abnormality 0 11DISCUSSION
Although encouraging, the results of this study can-
not be taken too far (particularly the comparative data).
General practitioners who refer women with epilepsy
for pre-conception counselling may practice a differ-
ent standard of care from those who do not. Women
who seek pre-conception counselling and who are
prepared not to get pregnant whilst undergoing drug
changes almost certainly have different educational,
social and health backgrounds from women who get
pregnant, without forethought, whilst taking AEDs.
We did not, in this retrospective study, enquire into
the smoking, drinking and illicit drug use habits of ourcontrol group, nor into their nutritional status, but they
may well have been different.
Likewise, the already pregnant group were referred
because of problematic epilepsy and we do not know
the universe from which they were drawn. It is likely
however that women attending the maternity hospital
with well-controlled epilepsy would be unlikely to be
referred, as the main reason for referral was to get bet-
ter control of the epilepsy before delivery. What the
study does show is that it is possible, at least with
some women, to reduce the total burden of AED use
before conception in women with epilepsy, to with-
draw it altogether in some (although some women eli-
gible for total withdrawal may not wish to), to ration-
alize to monotherapy in most and to be able to al-
most completely withdraw the more teratogenic AEDs
(phenobarbitone, phenytoin and valproate). In a group
of 85 patients we would have expected perhaps three
or four foetal anomalies3, possibly including a spina
bifida baby.
The fact that we did not encounter any is encourag-
ing but not conclusive, despite the high abnormality
rate in the control group. Even if there is a genuine re-
duction in abnormalities what is it due to? Drug with-
drawal, particularly valproate, or folic acid—or both?
It is impossible to say and only a larger, longer and
carefully controlled prospective study will elucidate
the answer to this question. It is important to remem-
ber that we made no note of minor anomalies such as
nail hypoplasia and can make no predictions about any
future educational and learning outcome in these chil-
dren.
However, we are encouraged by these results and
will continue our present practice of pre-conception
counselling. The question we have not answered is
whether to try to withdraw carbamazepine more of-
ten. It is implicated in teratogenesis4 but is a difficult
drug to withdraw completely and substitution is not al-
ways effective. Our present policy is to reduce the dose
as much as possible but not necessarily to completely
withdraw it. The study does show that complete reap-
praisal and re-investigation of a woman’s epilepsy is
valuable before she becomes pregnant: four women
who did not have epilepsy did not have to conceive
whilst taking un-needed AEDs and several women un-
derwent surgical treatment before conception. We also
learnt about the unspoken fears of our patients, which
will improve our counselling skills.
The real answer to pre-conception counselling and
drug change, however, is to educate the adolescent girl
fully about her epilepsy, investigate it thoroughly (so
that there are no nasty surprises during labour) and to
avoid using the older, more teratogenic, drugs from the
start of treatment. This will involve a sea change in
medical practice—but a very necessary one.
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131–137.CONCLUSION
Audit of the results of proactive pre-conception coun-
selling in a group of women with epilepsy suggests
that pre-conceptual re-investigation of the epilepsy,
withdrawal and rationalization of medication (with oc-
casional substitution of newer, possibly less terato-
genic AEDs) and prescription of folic acid 5 mg indef-
initely may reduce the frequency of severe foetal ab-
normality. The evidence is not fully conclusive but en-
courages us to continue our practice of pre-conception
counselling. Large-scale long-term studies are needed
to answer the questions our study has raised and it is
important that all pregnancies in women with epilepsy,
having seizures or not, on medication or not, are in-
cluded in an epilepsy and pregnancy register.REFERENCES
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